Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WP 1122

Next Previous
Drug Profile

WP 1122

Alternative Names: 2-DG prodrug; WP-1122; WP-1234

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Moleculin Biotech
  • Class Antineoplastics; Antivirals; Deoxy sugars; Small molecules
  • Mechanism of Action Coronavirus spike glycoprotein modulators; Glycolysis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer; COVID 2019 infections; Glioblastoma; Pancreatic cancer
  • Preclinical HIV infections; Viral haemorrhagic fevers

Most Recent Events

  • 22 Mar 2024 WP 1122 is still in preclinical trials for Glioblastoma in USA prior to March 2024 (Moleculin Biotech pipeline, March 2024)
  • 22 Mar 2024 WP 1122 is still in preclinical trials for Pancreatic cancer in USA prior to March 2024 (Moleculin Biotech pipeline, March 2024)
  • 22 Mar 2024 Phase-I clinical trials in Cancer (IV) as of March 2024 (Moleculin Biotech pipeline, March 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top